Bronchial Hyperreactivity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major bronchial hyperreactivity markets reached a value of US$ 13.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 22.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.93% during 2024-2034.
The bronchial hyperreactivity market has been comprehensively analyzed in IMARC's new report titled "Bronchial Hyperreactivity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchial hyperreactivity, also known as airway hyperresponsiveness, refers to an exaggerated sensitivity of the airways in the lungs to various environmental triggers. Individuals suffering from this illness may exhibit hyperactive airways, which tend to narrow and constrict more easily than those of healthy people, often leading to respiratory symptoms. Some common indications associated with the disease include recurrent episodes of wheezing, coughing, shortness of breath, and chest tightness. These symptoms can differ in intensity and frequency and are often exacerbated by exposure to allergens, cold air, exercise, or respiratory infections. The diagnosis of bronchial hyperreactivity usually involves a combination of clinical history, physical examination, and specialized tests. One primary diagnostic tool is the bronchial challenge test, where a patient inhales increasing doses of a substance like methacholine, which can induce bronchoconstriction. A positive test, characterized by a significant decrease in lung function measured by spirometry after exposure, confirms the presence of the disease.
The escalating incidence of environmental pollutants and allergens, which can agitate the airways and induce inflammation, is primarily driving the bronchial hyperreactivity market. In addition to this, the inflating utilization of efficacious medications, such as corticosteroids, bronchodilators, leukotriene modifiers, etc., to manage and control the inflammatory processes in patients is also creating a positive outlook for the market. Moreover, the widespread adoption of allergen avoidance strategies and lifestyle modifications, as they play a pivotal role in reducing triggers and improving overall respiratory health, is further bolstering the market growth. Apart from this, the rising usage of physical therapy and breathing exercises on account of their various benefits, such as enhancing lung function, promoting better breathing control, and mitigating bronchial hyperreactivity episodes, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine which encompasses the development of targeted therapies based on individual patient characteristics and genetic predispositions to address specific genetic markers associated with heightened bronchial sensitivity, is also augmenting the market growth. Furthermore, the increasing application of immunotherapy approaches, such as allergen-specific immunoglobulin E (IgE), that aim for desensitization and long-term symptom management is expected to drive the bronchial hyperreactivity market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the bronchial hyperreactivity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchial hyperreactivity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchial hyperreactivity market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bronchial hyperreactivity market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bronchial hyperreactivity market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bronchial hyperreactivity marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bronchial hyperreactivity market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bronchial hyperreactivity market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bronchial hyperreactivity market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bronchial hyperreactivity across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchial hyperreactivity by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchial hyperreactivity by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bronchial hyperreactivity across the seven major markets?
What is the size of the bronchial hyperreactivity patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bronchial hyperreactivity?
What will be the growth rate of patients across the seven major markets?
Bronchial Hyperreactivity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bronchial hyperreactivity drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchial hyperreactivity market?
What are the key regulatory events related to the bronchial hyperreactivity market?
What is the structure of clinical trial landscape by status related to the bronchial hyperreactivity market?
What is the structure of clinical trial landscape by phase related to the bronchial hyperreactivity market?
What is the structure of clinical trial landscape by route of administration related to the bronchial hyperreactivity market?
The bronchial hyperreactivity market has been comprehensively analyzed in IMARC's new report titled "Bronchial Hyperreactivity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchial hyperreactivity, also known as airway hyperresponsiveness, refers to an exaggerated sensitivity of the airways in the lungs to various environmental triggers. Individuals suffering from this illness may exhibit hyperactive airways, which tend to narrow and constrict more easily than those of healthy people, often leading to respiratory symptoms. Some common indications associated with the disease include recurrent episodes of wheezing, coughing, shortness of breath, and chest tightness. These symptoms can differ in intensity and frequency and are often exacerbated by exposure to allergens, cold air, exercise, or respiratory infections. The diagnosis of bronchial hyperreactivity usually involves a combination of clinical history, physical examination, and specialized tests. One primary diagnostic tool is the bronchial challenge test, where a patient inhales increasing doses of a substance like methacholine, which can induce bronchoconstriction. A positive test, characterized by a significant decrease in lung function measured by spirometry after exposure, confirms the presence of the disease.
The escalating incidence of environmental pollutants and allergens, which can agitate the airways and induce inflammation, is primarily driving the bronchial hyperreactivity market. In addition to this, the inflating utilization of efficacious medications, such as corticosteroids, bronchodilators, leukotriene modifiers, etc., to manage and control the inflammatory processes in patients is also creating a positive outlook for the market. Moreover, the widespread adoption of allergen avoidance strategies and lifestyle modifications, as they play a pivotal role in reducing triggers and improving overall respiratory health, is further bolstering the market growth. Apart from this, the rising usage of physical therapy and breathing exercises on account of their various benefits, such as enhancing lung function, promoting better breathing control, and mitigating bronchial hyperreactivity episodes, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine which encompasses the development of targeted therapies based on individual patient characteristics and genetic predispositions to address specific genetic markers associated with heightened bronchial sensitivity, is also augmenting the market growth. Furthermore, the increasing application of immunotherapy approaches, such as allergen-specific immunoglobulin E (IgE), that aim for desensitization and long-term symptom management is expected to drive the bronchial hyperreactivity market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the bronchial hyperreactivity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchial hyperreactivity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchial hyperreactivity market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bronchial hyperreactivity market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bronchial hyperreactivity market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bronchial hyperreactivity marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bronchial hyperreactivity market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bronchial hyperreactivity market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bronchial hyperreactivity market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bronchial hyperreactivity across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchial hyperreactivity by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchial hyperreactivity by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bronchial hyperreactivity across the seven major markets?
What is the size of the bronchial hyperreactivity patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bronchial hyperreactivity?
What will be the growth rate of patients across the seven major markets?
Bronchial Hyperreactivity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bronchial hyperreactivity drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchial hyperreactivity market?
What are the key regulatory events related to the bronchial hyperreactivity market?
What is the structure of clinical trial landscape by status related to the bronchial hyperreactivity market?
What is the structure of clinical trial landscape by phase related to the bronchial hyperreactivity market?
What is the structure of clinical trial landscape by route of administration related to the bronchial hyperreactivity market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BRONCHIAL HYPERREACTIVITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BRONCHIAL HYPERREACTIVITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BRONCHIAL HYPERREACTIVITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BRONCHIAL HYPERREACTIVITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BRONCHIAL HYPERREACTIVITY - UNMET NEEDS
10 BRONCHIAL HYPERREACTIVITY - KEY ENDPOINTS OF TREATMENT
11 BRONCHIAL HYPERREACTIVITY - MARKETED PRODUCTS
11.1 List of Bronchial Hyperreactivity Marketed Drugs Across the Top 7 Markets
11.1.1 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Tezspire (Tezepelumab) - Amgen/AstraZeneca
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Dulera (Mometasone/formoterol) - Merck & Co/Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Alvesco (Ciclesonide) - AstraZeneca/Covis Pharma/Takeda
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Breo Ellipta (Fluticasone furoate/vilanterol) - GSK/Innoviva
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BRONCHIAL HYPERREACTIVITY - PIPELINE DRUGS
12.1 List of Bronchial Hyperreactivity Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 BRONCHIAL HYPERREACTIVITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 BRONCHIAL HYPERREACTIVITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BRONCHIAL HYPERREACTIVITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bronchial Hyperreactivity - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bronchial Hyperreactivity - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bronchial Hyperreactivity - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bronchial Hyperreactivity - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bronchial Hyperreactivity - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bronchial Hyperreactivity - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bronchial Hyperreactivity - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bronchial Hyperreactivity - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bronchial Hyperreactivity - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bronchial Hyperreactivity - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bronchial Hyperreactivity - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bronchial Hyperreactivity - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bronchial Hyperreactivity - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bronchial Hyperreactivity - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bronchial Hyperreactivity - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bronchial Hyperreactivity - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
16 BRONCHIAL HYPERREACTIVITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BRONCHIAL HYPERREACTIVITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BRONCHIAL HYPERREACTIVITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BRONCHIAL HYPERREACTIVITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BRONCHIAL HYPERREACTIVITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BRONCHIAL HYPERREACTIVITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BRONCHIAL HYPERREACTIVITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BRONCHIAL HYPERREACTIVITY - UNMET NEEDS
10 BRONCHIAL HYPERREACTIVITY - KEY ENDPOINTS OF TREATMENT
11 BRONCHIAL HYPERREACTIVITY - MARKETED PRODUCTS
11.1 List of Bronchial Hyperreactivity Marketed Drugs Across the Top 7 Markets
11.1.1 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Tezspire (Tezepelumab) - Amgen/AstraZeneca
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Dulera (Mometasone/formoterol) - Merck & Co/Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Alvesco (Ciclesonide) - AstraZeneca/Covis Pharma/Takeda
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Breo Ellipta (Fluticasone furoate/vilanterol) - GSK/Innoviva
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BRONCHIAL HYPERREACTIVITY - PIPELINE DRUGS
12.1 List of Bronchial Hyperreactivity Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 BRONCHIAL HYPERREACTIVITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 BRONCHIAL HYPERREACTIVITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BRONCHIAL HYPERREACTIVITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bronchial Hyperreactivity - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bronchial Hyperreactivity - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bronchial Hyperreactivity - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bronchial Hyperreactivity - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bronchial Hyperreactivity - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bronchial Hyperreactivity - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bronchial Hyperreactivity - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bronchial Hyperreactivity - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bronchial Hyperreactivity - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bronchial Hyperreactivity - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bronchial Hyperreactivity - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bronchial Hyperreactivity - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bronchial Hyperreactivity - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bronchial Hyperreactivity - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bronchial Hyperreactivity - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bronchial Hyperreactivity - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bronchial Hyperreactivity - Access and Reimbursement Overview
16 BRONCHIAL HYPERREACTIVITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BRONCHIAL HYPERREACTIVITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BRONCHIAL HYPERREACTIVITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
